1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Merck & Co., Inc.

Merck & Co., Inc.

MRK.PA
Merck & Co., Inc.undefined flagEuronext Paris
101.40
EUR
- -
- -
260.61BMarket Cap
Merck & Co., Inc.
MRK.PA
(Euronext Paris)

Recent

price

101.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
14.86
15.8
15.62
15.04
14.88
14.2
14.48
14.88
16.31
15.41
16.41
19.25
23.41
23.06
- -
- -
- -
Revenue per Share
0.28
2.06
2.04
1.5
4.2
1.6
1.43
0.89
2.4
3.88
2.79
5.16
5.73
0.14
- -
- -
- -
Basic EPS, GAAP
3.5
4.07
3.31
3.98
2.46
4.51
3.77
2.39
4.21
5.29
4.05
5.58
7.54
4.99
- -
- -
- -
Free Cash Flow per Basic Share
1.57
1.58
1.73
1.8
1.85
1.84
1.86
1.92
1.99
2.24
2.46
2.61
2.77
2.86
- -
- -
- -
Dividend per Share
12.71
13.41
13.8
14.02
16.85
16.95
16.71
16
17.11
19.06
19.43
21.93
24.83
21.36
- -
- -
- -
Book Value per Share
1.61
3.45
4.71
5.54
5.43
1.6
1.76
0.78
-1.73
-3
-3
-2.35
1.81
-0.6
- -
- -
- -
Tangible Book Value per Share
3,095
3,041
3,027
2,928
2,838
2,781
2,749
2,697
2,593
2,539
2,530
2,530
2,532
2,607
- -
- -
- -
Basic Weighted Avg Shares
45,987
48,047
47,267
44,033
42,237
39,498
39,807
40,122
42,294
39,121
41,518
48,704
59,283
60,115
64,168
65,011
65,768
Sales/Revenue/Turnover
7.3
18.68
20.9
17.41
15.82
19.11
13.81
16.94
21.12
20.26
13.36
27.1
30.84
4.91
31.51
34.01
19.72
Operating Margin (%)
7,381
7,427
6,978
6,988
6,691
6,375
5,471
4,676
4,519
3,310
3,486
3,214
3,909
3,872
4,499
5,838
6,251
Depreciation Expense
861
6,272
6,168
4,404
11,920
4,442
3,920
2,394
6,220
9,843
7,067
13,049
14,519
365
17,117
18,254
8,935
Net Income, GAAP
40.59
12.84
27.92
18.54
30.95
17.44
15.41
62.92
28.82
21.82
22.86
10.96
11.66
80.04
14.06
13.31
23.18
Effective Tax Rate (%)
1.87
13.05
13.05
10
28.22
11.25
9.85
5.97
14.71
25.16
17.02
26.79
24.49
0.61
26.68
28.08
13.59
Profit Margin (%)
13,423
16,936
16,509
17,817
14,208
10,550
13,410
6,152
3,669
5,263
437
6,394
11,483
6,474
10,362
15,189
8,070
Working Capital
15,482
15,525
16,254
20,539
18,699
23,829
24,274
21,353
19,806
22,736
25,360
30,690
28,745
33,683
34,462
46,750
46,673
LT Debt
56,805
56,943
55,463
52,326
48,791
44,767
40,308
34,569
26,882
26,001
25,404
38,257
46,058
37,635
46,372
52,662
45,931
Total Equity
2.56
10.37
9.36
8.08
6.2
8.66
6.66
3.98
11.21
11.6
7.66
17.91
21.36
0.77
21.38
19.76
10.64
Return on Invested Capital (%)
1.9
11.23
10.44
7.41
17.98
6.96
6.2
3.82
9.89
20.46
13.16
17.04
16.85
0.63
18.87
17.17
9.17
Return on Capital (%)
2.09
15.62
14.94
10.64
26.83
9.36
8.42
5.38
14.22
21.22
14.49
24.94
24.54
0.62
28.4
26.13
13.1
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,405
2,589
2,444
LT Borrowings
39,969
46,750
46,673
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,487
2,475
2,470
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
47,557
43,516
35,015
Cash, Cash Equivalents & STI
18,214
14,565
5,702
Accounts Receivable, Net
12,120
11,775
12,210
Inventories
6,444
6,658
6,479
Total Current Liabilities
28,628
28,327
26,945
Payables & Accruals
27,223
25,738
24,501
ST Debt
1,405
2,589
2,444
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.75%
17.89%
13.56%
Free Cash Flow
9.64%
16.57%
-23.27%
Net Income, GAAP
473.39%
918.93%
6.64%
Sales/Revenue/Turnover
5.41%
9.7%
1.31%
Total Cash Common Dividend
4.85%
5.64%
4.29%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,775
16,112
16,657
15,624
64,168
2025
15,529
15,806
17,276
16,400
65,011
2026
16,286
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.88
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.77
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Zoetis Inc. (ZTS)
PT Kalbe Farma Tbk. (KLBF.JK)
PT Kalbe Farma Tbk (PTKFY)
Vigonvita Life Sciences Co., Ltd. (2630.HK)
Horizon Therapeutics Public Limited Company (HZNP)
Genovate Biotechnology Co., Ltd. (4130.TWO)
Business
Merck & Co., Inc. is a global healthcare company headquartered in Rahway, New Jersey, founded in 1891. It discovers, develops, manufactures, and markets pharmaceuticals, vaccines, biologic therapies, and animal health products. Its core pharmaceutical products include Keytruda (pembrolizumab) for cancer immunotherapy; Lynparza (olaparib) for BRCA-mutated ovarian cancer; Lenvima (lenvatinib) for thyroid cancer; Welireg (belzutifan) for von Hippel–Lindau disease-associated renal cell carcinoma; and Reblozyl (luspatercept) for anemia treatment. Merck’s vaccine portfolio includes Gardasil for human papillomavirus (HPV), ProQuad/M-M-R II/Varivax combination vaccines against measles, mumps, rubella, and varicella, as well as Pneumovax 23 and other vaccines for infectious diseases. The animal health segment offers vaccines and pharmaceutical products for livestock and companion animals. Recent major developments include the pending acquisition of Verona Pharma, which adds Ohtuvayre, a first-in-class dual phosphodiesterase 3 and 4 inhibitor for chronic obstructive pulmonary disease (COPD) treatment, approved by the FDA in June 2024. Merck also announced a multiyear optimization initiative expected to save $3 billion annually by 2027, redirecting investments to its growth drivers and pipeline, alongside a restructuring program focusing on administrative and R&D efficiencies. Expansion projects include a $1 billion biologics center of excellence in Wilmington, Delaware, for Keytruda production and an $895 million expansion of its animal health manufacturing facility in Kansas. Merck operates globally with key markets in the U.S., Europe, the Middle East, Africa, China, Japan, and Latin America. It serves a broad range of customers across oncology, immunology, infectious diseases, and animal health sectors. The company continues to invest heavily in research, manufacturing, and commercial capabilities to support innovation-driven growth and strategic pipeline development. This description incorporates Merck’s comprehensive product portfolio, strategic acquisitions, and recent operational adjustments reflecting its drive to maintain leadership in pharmaceuticals and vaccines while expanding its cardio-pulmonary and animal health offerings.